{"id":"W2893246991","doi":"10.1136/annrheumdis-2018-eular.5146","title":"AB0954 A randomised, double-blind trial comparing the efficacy, safety and immunogenicity of msb11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Psoriasis Area and Severity Index; Biosimilar; Psoriatic arthritis; Tolerability; Clinical endpoint; Bioequivalence; Internal medicine; Psoriasis; Interim analysis; Clinical trial; Adverse effect; Rheumatoid arthritis; Dermatology; Pharmacokinetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007305533,0.0002711345,0.0009629517,0.0001113207,0.0001710335,0.00001650472,0.0005433217,0.0001513682,0.00008973027],"category_scores_gemma":[0.0005113623,0.0001402166,0.0002445409,0.000396454,0.0009478162,0.00007797106,0.0002318882,0.0001715844,0.00000214168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002146392,"about_ca_system_score_gemma":0.0001675951,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002706268,"about_ca_topic_score_gemma":0.0000742078,"domain_scores_codex":[0.9976525,0.000631269,0.000905273,0.0002986665,0.0001821541,0.0003301228],"domain_scores_gemma":[0.9974744,0.000979402,0.0005717462,0.0006039334,0.0003130283,0.00005751958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9907688,0.001336816,0.002948124,0.0001523166,0.001272628,2.23869e-7,0.0004938975,0.00005078712,0.0002143756,0.0003987517,0.0001761712,0.002187126],"study_design_scores_gemma":[0.8823557,0.003880966,0.05968078,0.001210816,0.000965677,0.000001799268,0.0002691674,0.0001953319,0.0504246,0.000362444,0.0002125398,0.0004401162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960082,0.0007017486,0.00003422684,0.0005279935,0.00031429,0.002112614,0.0001903235,0.00001104708,0.00009961054],"genre_scores_gemma":[0.9996064,0.0001127081,0.0001159635,0.00007960775,0.00001305329,0.00002328675,0.00001275621,0.0000162272,0.00001998165],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.108413,"threshold_uncertainty_score":0.5717868,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05245146854743497,"score_gpt":0.3175573006045067,"score_spread":0.2651058320570717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}